Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation

Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation - Surprise study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002744

Enrollment

300

Registered

2009-11-10

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

tocilizumab plus methotrexate tocilizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with rheumatoid arthritis diagnosed according to the criteria of the American College of Rheumatology (ACR) 2) Patients treated with more than 6mg/week dose of methotrexate for more than 8 weeks 3) Patients whose disease duration are less than 10 years 4) DAS28-ESR score less than 3.2 at the time of entry

Exclusion criteria

Exclusion criteria: 1) Patients whose Steinbrocker functional classification are class 4 2) Patients treated with leflunomide, disease modifying anti-rhuematic disease drugs without methotrexate, or tacrolimus 3) Patients who have ever treated with any of biologic agents 4) Patients treated with 10mg/day of predonisolone 5) Patients whose WBC is less than 4000 or lymphocytes is less than 1000 6) Patients with infection of HBV or EBV

Design outcomes

Primary

Measure	Time frame
remission rate at 24 weeks (DAS28-ESR)	—

Countries

Japan

Contacts

Public ContactYuko Kaneko

Department of Internal Medicine, Keio University School of Medicine Division of Rheumatology

ykaneko@z6.keio.jp0333531211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026